Report
Valens Research

GKOS - Embedded Expectations Analysis - 2017 11 30

Although management's concerns imply the potential for near-term headwinds, longer-term tailwinds remain that support further equity upside

Underlying
Glaukos Corp

Glaukos is an ophthalmic medical technology and pharmaceutical company focused on surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. The company developed Micro-Invasive Glaucoma Surgery (MIGS) to serve as an alternative to the glaucoma treatment and management paradigm. MIGS procedures involve the insertion of a micro-scale device or drug delivery system from within the eye's anterior chamber through a small corneal incision. The company's MIGS devices are designed to reduce intraocular pressure by restoring the natural outflow pathways for aqueous humor. The company's products include iStent trabecular micro-bypass stent, and iStent Inject trabecular micro-bypass stent.

Provider
Valens Research
Valens Research

In 2009, just as the dust was settling from the last major equity and credit market crises, we launched a boutique research firm with the intention of breaking Wall Street’s biases and broken incentives:

  • GAAP and IFRS have failed to provide rules for reliable financial statement reporting
  • Stock analyst recommendations are not grounded in disciplined financial analysis
  • Credit agencies have been set up to grossly fail in their responsibilities to investors and the public markets
  • Utter lack of willingness of major research firms to employ the the most advanced forensic analysis available

We sought to provide investors and company analysts with a source of information that changed all that.
Many years later, our business model remains because little has changed on Wall Street.

  • Corporate credit ratings remain years behind the fundamental underpinnings of company performance
  • Stock analysts continue to make recommendations with deeply inherent biases
  • Research firms have failed to break down the walls between credit, equity, and macroeconomic research
  • The governing accounting bodies have created more leeway for mis-estimates and mis-classifications as financials have become unwieldy and overwhelming

The integrity of Valens Research is founded in our disciplined processes and analytics. No “star” analysts. No corporate advisory relationships. No-nonsense opinions and recommendations.

Analysts
Valens Research

Other Reports on these Companies
Other Reports from Valens Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch